Exact Mass: 487.3199
Exact Mass Matches: 487.3199
Found 500 metabolites which its exact mass value is equals to given mass value 487.3199,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine
(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine
(4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine
(4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine
(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine
(4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine
(4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine
(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine
(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine
(4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine
(4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine
(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Talaroconvolutin A
An octahydronaphthalene with formula C32H41NO3. It is a fungal metabolite isolated from Talaromyces convolutus and is an inducer of ferroptosis in colorectal cancer cells.
Asn Val Lys Lys
Asn Lys Val Lys
Thr Ile Val Arg
Ala Ile Val Trp
Ala Ile Trp Val
Ala Lys Asn Arg
Ala Lys Arg Asn
Ala Leu Val Trp
Ala Leu Trp Val
Ala Asn Lys Arg
Ala Asn Arg Lys
Ala Arg Lys Asn
Ala Arg Asn Lys
Ala Val Ile Trp
Ala Val Leu Trp
Ala Val Trp Ile
Ala Val Trp Leu
Ala Trp Ile Val
Ala Trp Leu Val
Ala Trp Val Ile
Ala Trp Val Leu
Asp Ile Ile Lys
Asp Ile Lys Ile
Asp Ile Lys Leu
Asp Ile Leu Lys
Asp Lys Ile Ile
Asp Lys Ile Leu
Asp Lys Leu Ile
Asp Lys Leu Leu
Asp Leu Ile Lys
Asp Leu Lys Ile
Asp Leu Lys Leu
Asp Leu Leu Lys
Glu Ile Lys Val
Glu Ile Val Lys
Glu Lys Ile Val
Glu Lys Leu Val
Glu Lys Val Ile
Glu Lys Val Leu
Glu Leu Lys Val
Glu Leu Val Lys
Glu Val Ile Lys
Glu Val Lys Ile
Glu Val Lys Leu
Glu Val Leu Lys
Phe Lys Pro Pro
Phe Pro Lys Pro
Phe Pro Pro Lys
Gly Ile Ile Trp
Gly Ile Leu Trp
Gly Ile Trp Ile
Gly Ile Trp Leu
Gly Lys Lys Arg
Gly Lys Gln Arg
Gly Lys Arg Lys
Gly Lys Arg Gln
Gly Leu Ile Trp
Gly Leu Leu Trp
Gly Leu Trp Ile
Gly Leu Trp Leu
Gly Gln Lys Arg
Gly Gln Arg Lys
Gly Arg Lys Lys
Gly Arg Lys Gln
Gly Arg Gln Lys
Gly Trp Ile Ile
Gly Trp Ile Leu
Gly Trp Leu Ile
Gly Trp Leu Leu
Ile Ala Val Trp
Ile Ala Trp Val
Ile Asp Ile Lys
Ile Asp Lys Ile
Ile Asp Lys Leu
Ile Asp Leu Lys
Ile Glu Lys Val
Ile Glu Val Lys
Ile Gly Ile Trp
Ile Gly Leu Trp
Ile Gly Trp Ile
Ile Gly Trp Leu
Ile Ile Asp Lys
Ile Ile Gly Trp
Ile Ile Lys Asp
Ile Ile Arg Ser
Ile Ile Ser Arg
Ile Ile Trp Gly
Ile Lys Asp Ile
Ile Lys Asp Leu
Ile Lys Glu Val
Ile Lys Ile Asp
Ile Lys Leu Asp
Ile Lys Met Pro
Ile Lys Pro Met
Ile Lys Val Glu
Ile Leu Asp Lys
Ile Leu Gly Trp
Ile Leu Lys Asp
Ile Leu Arg Ser
Ile Leu Ser Arg
Ile Leu Trp Gly
Ile Met Lys Pro
Ile Met Pro Lys
Ile Pro Lys Met
Ile Pro Met Lys
Ile Arg Ile Ser
Ile Arg Leu Ser
Ile Arg Ser Ile
Ile Arg Ser Leu
Ile Arg Thr Val
Ile Arg Val Thr
Ile Ser Ile Arg
Ile Ser Leu Arg
Ile Ser Arg Ile
Ile Ser Arg Leu
Ile Thr Arg Val
Ile Thr Val Arg
Ile Val Ala Trp
Ile Val Glu Lys
Ile Val Lys Glu
Ile Val Arg Thr
Ile Val Thr Arg
Ile Val Trp Ala
Ile Trp Ala Val
Ile Trp Gly Ile
Ile Trp Gly Leu
Ile Trp Ile Gly
Ile Trp Leu Gly
Lys Ala Asn Arg
Lys Ala Arg Asn
Lys Asp Ile Ile
Lys Asp Ile Leu
Lys Asp Leu Ile
Lys Asp Leu Leu
Lys Glu Ile Val
Lys Glu Leu Val
Lys Glu Val Ile
Lys Glu Val Leu
Lys Gly Lys Arg
Lys Gly Gln Arg
Lys Gly Arg Lys
Lys Gly Arg Gln
Lys Ile Asp Ile
Lys Ile Asp Leu
Lys Ile Glu Val
Lys Ile Ile Asp
Lys Ile Leu Asp
Lys Ile Met Pro
Lys Ile Pro Met
Lys Ile Val Glu
Lys Lys Gly Arg
Lys Lys Asn Val
Lys Lys Arg Gly
Lys Lys Val Asn
Lys Leu Asp Ile
Lys Leu Asp Leu
Lys Leu Glu Val
Lys Leu Ile Asp
Lys Leu Leu Asp
Lys Leu Met Pro
Lys Leu Pro Met
Lys Leu Val Glu
Lys Met Ile Pro
Lys Met Leu Pro
Lys Met Pro Ile
Lys Met Pro Leu
Lys Asn Ala Arg
Lys Asn Lys Val
Lys Asn Arg Ala
Lys Asn Val Lys
Lys Pro Ile Met
Lys Pro Leu Met
Lys Pro Met Ile
Lys Pro Met Leu
Lys Gln Gly Arg
Lys Gln Arg Gly
Lys Arg Ala Asn
Lys Arg Gly Lys
Lys Arg Gly Gln
Lys Arg Lys Gly
Lys Arg Asn Ala
Lys Arg Gln Gly
Lys Val Glu Ile
Lys Val Glu Leu
Lys Val Ile Glu
Lys Val Lys Asn
Lys Val Leu Glu
Lys Val Asn Lys
Leu Asp Ile Lys
Leu Asp Lys Ile
Leu Asp Lys Leu
Leu Asp Leu Lys
Leu Glu Lys Val
Leu Glu Val Lys
Leu Ile Asp Lys
Leu Ile Lys Asp
Leu Ile Arg Ser
Leu Ile Ser Arg
Leu Lys Asp Ile
Leu Lys Asp Leu
Leu Lys Glu Val
Leu Lys Ile Asp
Leu Lys Leu Asp
Leu Lys Met Pro
Leu Lys Pro Met
Leu Lys Val Glu
Leu Leu Asp Lys
Leu Leu Lys Asp
Leu Leu Arg Ser
Leu Leu Ser Arg
Leu Met Lys Pro
Leu Met Pro Lys
Leu Pro Lys Met
Leu Pro Met Lys
Leu Arg Ile Ser
Leu Arg Leu Ser
Leu Arg Ser Ile
Leu Arg Ser Leu
Leu Arg Thr Val
Leu Arg Val Thr
Leu Ser Ile Arg
Leu Ser Leu Arg
Leu Ser Arg Ile
Leu Ser Arg Leu
Leu Thr Arg Val
Leu Thr Val Arg
Leu Val Glu Lys
Leu Val Lys Glu
Leu Val Arg Thr
Leu Val Thr Arg
Met Ile Lys Pro
Met Ile Pro Lys
Met Lys Ile Pro
Met Lys Leu Pro
Met Lys Pro Ile
Met Lys Pro Leu
Met Leu Lys Pro
Met Leu Pro Lys
Met Pro Ile Lys
Met Pro Lys Ile
Met Pro Lys Leu
Met Pro Leu Lys
Asn Ala Lys Arg
Asn Ala Arg Lys
Asn Lys Ala Arg
Asn Lys Lys Val
Asn Lys Arg Ala
Asn Arg Ala Lys
Asn Arg Lys Ala
Pro Ile Lys Met
Pro Ile Met Lys
Pro Lys Ile Met
Pro Lys Leu Met
Pro Lys Met Ile
Pro Lys Met Leu
Pro Leu Lys Met
Pro Leu Met Lys
Pro Met Ile Lys
Pro Met Lys Ile
Pro Met Lys Leu
Pro Met Leu Lys
Gln Gly Lys Arg
Gln Gly Arg Lys
Gln Lys Gly Arg
Gln Lys Arg Gly
Gln Arg Gly Lys
Gln Arg Lys Gly
Arg Ala Lys Asn
Arg Ala Asn Lys
Arg Gly Lys Lys
Arg Gly Lys Gln
Arg Gly Gln Lys
Arg Ile Ile Ser
Arg Ile Leu Ser
Arg Ile Ser Ile
Arg Ile Ser Leu
Arg Ile Thr Val
Arg Ile Val Thr
Arg Lys Ala Asn
Arg Lys Gly Lys
Arg Lys Gly Gln
Arg Lys Lys Gly
Arg Lys Asn Ala
Arg Lys Gln Gly
Arg Leu Ile Ser
Arg Leu Leu Ser
Arg Leu Ser Ile
Arg Leu Ser Leu
Arg Leu Thr Val
Arg Leu Val Thr
Arg Asn Ala Lys
Arg Asn Lys Ala
Arg Gln Gly Lys
Arg Gln Lys Gly
Arg Ser Ile Ile
Arg Ser Ile Leu
Arg Ser Leu Ile
Arg Ser Leu Leu
Arg Thr Ile Val
Arg Thr Leu Val
Arg Thr Val Ile
Arg Thr Val Leu
Arg Val Ile Thr
Arg Val Leu Thr
Arg Val Thr Ile
Arg Val Thr Leu
Ser Ile Ile Arg
Ser Ile Leu Arg
Ser Ile Arg Ile
Ser Ile Arg Leu
Ser Leu Ile Arg
Ser Leu Leu Arg
Ser Leu Arg Ile
Ser Leu Arg Leu
Ser Arg Ile Ile
Ser Arg Ile Leu
Ser Arg Leu Ile
Ser Arg Leu Leu
Thr Ile Arg Val
Thr Leu Arg Val
Thr Leu Val Arg
Thr Arg Ile Val
Thr Arg Leu Val
Thr Arg Val Ile
Thr Arg Val Leu
Thr Val Ile Arg
Thr Val Leu Arg
Thr Val Arg Ile
Thr Val Arg Leu
Val Glu Ile Lys
Val Glu Lys Ile
Val Glu Lys Leu
Val Glu Leu Lys
Val Ile Glu Lys
Val Ile Lys Glu
Val Ile Arg Thr
Val Ile Thr Arg
Val Lys Glu Ile
Val Lys Glu Leu
Val Lys Ile Glu
Val Lys Lys Asn
Val Lys Leu Glu
Val Lys Asn Lys
Val Leu Glu Lys
Val Leu Lys Glu
Val Leu Arg Thr
Val Leu Thr Arg
Val Asn Lys Lys
Val Arg Ile Thr
Val Arg Leu Thr
Val Arg Thr Ile
Val Arg Thr Leu
Val Thr Ile Arg
Val Thr Leu Arg
Val Thr Arg Ile
Val Thr Arg Leu
2-(8-[3]-ladderane-octanyl)-sn-glycero-3-phosphoethanolamine
Poly(oxy-1,2-ethanediyl), .alpha.-sulfo- .omega.-(dinonylphenoxy)-, ammonium salt
1-Octanaminium,N-[2-[(2,2-dicyclopentylacetyl)oxy]ethyl]-N,N-diethyl-, bromide (1:1)
sodium glycocholate
D005765 - Gastrointestinal Agents > D002756 - Cholagogues and Choleretics D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids D013501 - Surface-Active Agents > D003902 - Detergents Glycocholic acid sodium is an orally active bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1]. Glycocholic acid sodium is an orally active bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1].
Beauveriolide I
A cyclodepsipeptide with formula C27H41N3O5. It was originally isolated from the fungus Beauveria sp. FO-6979 during a screening program for inhibitors of lipid droplet accumulation in murine macrophages. It is an inhibitor of acyl-CoA: cholesterol acyltransferase (ACAT) and effective at reducing atherogenic lesions of the artery and heart in mouse models.
(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine
(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine
(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine
(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine
(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine
(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine
(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine
(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine
(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine
(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine
(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine
[3-methyl-4-(3-methylphenyl)-1-piperazinyl]-[1-(7,8,9,10-tetrahydro-6H-purino[9,8-a]azepin-4-yl)-4-piperidinyl]methanone
(1S)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]-1-[4-(1-hydroxy-2-methylpropan-2-yl)phenyl]butan-1-ol
N-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
(2S,3S,3aR,9bR)-7-(cyclohexen-1-yl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-2-[oxo-[4-(phenylmethyl)-1-piperidinyl]methyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one
N-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
N-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
N-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7R,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7R,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
(1S,9R,10R,11R)-5-(cyclohexen-1-yl)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
N-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
N-[(4S,7R,8S)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7S,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4R,7S,8S)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(4S,7S,8S)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
(2R,3R,3aS,9bS)-7-(1-cyclohexenyl)-N-(2,3-dihydro-1H-inden-2-yl)-3-(hydroxymethyl)-6-oxo-1-propyl-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(1R,9S,10S,11S)-5-(cyclohexen-1-yl)-11-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-10-(hydroxymethyl)-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2S,3S,3aR,9bR)-7-(1-cyclohexenyl)-3-(hydroxymethyl)-2-[oxo-[4-(phenylmethyl)-1-piperidinyl]methyl]-1,2,3,3a,4,9b-hexahydropyrrolo[2,3-a]indolizin-6-one
2-aminoethyl [2-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propyl] hydrogen phosphate
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]dodeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]trideca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(undecanoylamino)pentadeca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(tridecanoylamino)trideca-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-(tetradecanoylamino)dodeca-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]undec-4-ene-1-sulfonic acid
(E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid
(4E,8E)-2-(decanoylamino)-3-hydroxyhexadeca-4,8-diene-1-sulfonic acid
(4E,8E)-2-(dodecanoylamino)-3-hydroxytetradeca-4,8-diene-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]dodec-4-ene-1-sulfonic acid
2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxydecane-1-sulfonic acid
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tridec-4-ene-1-sulfonic acid
4-(3-Heptanoyloxy-2-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-[2,3-Di(octanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate
4-(3-Propanoyloxy-2-tridecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Butanoyloxy-2-dodecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Pentanoyloxy-2-undecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(3-Acetyloxy-2-tetradecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
4-(2-Decanoyloxy-3-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
(1s,2r,5s,7r,8r,11s,14s)-1,2-dimethyl-18-(3-methylbut-2-en-1-yl)-7-(prop-1-en-2-yl)-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-9,16(24),17,19,21-pentaene-8,11-diol
[6-(2-{2-[5-(6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl)-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl}ethenyl)-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid
(1s,4s,10s,12s)-12-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione
(2s)-n-(5-{[(2s)-2,5-diamino-1-hydroxypentylidene]amino}pentyl)-2-{[1-hydroxy-2-(1h-indol-3-yl)ethylidene]amino}butanediimidic acid
23-o-acetyl-12β-hydroxysolasodine
{"Ingredient_id": "HBIN004134","Ingredient_name": "23-o-acetyl-12\u03b2-hydroxysolasodine","Alias": "23-O-acetyl-12\u03b2-hydroxysolasodine","Ingredient_formula": "C29H45NO5","Ingredient_Smile": "C29H45NO5","Ingredient_weight": "487.67","OB_score": "12.16578116","CAS_id": "117803-97-1","SymMap_id": "SMIT08805","TCMID_id": "37260","TCMSP_id": "MOL007352","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
